"Epidermal Growth Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.
| Descriptor ID |
D004815
|
| MeSH Number(s) |
D06.472.317.350 D12.644.276.382.500 D12.776.467.382.500 D23.529.382.500
|
| Concept/Terms |
Epidermal Growth Factor- Epidermal Growth Factor
- Growth Factor, Epidermal
- Urogastrone
- Epidermal Growth Factor-Urogastrone
- Growth Factor-Urogastrone, Epidermal
- Human Urinary Gastric Inhibitor
- beta-Urogastrone
- beta Urogastrone
- EGF
|
Below are MeSH descriptors whose meaning is more general than "Epidermal Growth Factor".
Below are MeSH descriptors whose meaning is more specific than "Epidermal Growth Factor".
This graph shows the total number of publications written about "Epidermal Growth Factor" by people in this website by year, and whether "Epidermal Growth Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 2 | 1 | 3 |
| 2001 | 3 | 1 | 4 |
| 2002 | 2 | 1 | 3 |
| 2003 | 4 | 2 | 6 |
| 2004 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 2 | 3 |
| 2014 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Epidermal Growth Factor" by people in Profiles.
-
Role of Runx2 in crosstalk between Mek/Erk and PI3K/Akt signaling in MCF-10A cells. J Cell Biochem. 2014 Dec; 115(12):2208-17.
-
Spatially defined InsP3-mediated signaling in embryonic stem cell-derived cardiomyocytes. PLoS One. 2014; 9(1):e83715.
-
Phosphoproteomics-based modeling defines the regulatory mechanism underlying aberrant EGFR signaling. PLoS One. 2010 Nov 10; 5(11):e13926.
-
Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration. J Biol Chem. 2011 Jan 07; 286(1):620-33.
-
Biglycan regulates the expression of EGF receptors through EGF signaling pathways in human articular chondrocytes. Connect Tissue Res. 2010 Oct; 51(5):347-58.
-
Temporal perturbation of tyrosine phosphoproteome dynamics reveals the system-wide regulatory networks. Mol Cell Proteomics. 2009 Feb; 8(2):226-31.
-
Regulation of oxidant-induced intestinal permeability by metalloprotease-dependent epidermal growth factor receptor signaling. J Pharmacol Exp Ther. 2007 Apr; 321(1):84-97.
-
Inhibition of oxidant-induced nuclear factor-kappaB activation and inhibitory-kappaBalpha degradation and instability of F-actin cytoskeletal dynamics and barrier function by epidermal growth factor: key role of phospholipase-gamma isoform. J Pharmacol Exp Ther. 2004 Apr; 309(1):356-68.
-
PKC-beta1 isoform activation is required for EGF-induced NF-kappaB inactivation and IkappaBalpha stabilization and protection of F-actin assembly and barrier function in enterocyte monolayers. Am J Physiol Cell Physiol. 2004 Mar; 286(3):C723-38.
-
Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin Investig Drugs. 2003 Aug; 12(8):1395-401.